Details for New Drug Application (NDA): 218047
✉ Email this page to a colleague
The generic ingredient in ERIBULIN MESYLATE is eribulin mesylate. Six suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.
Summary for 218047
Tradename: | ERIBULIN MESYLATE |
Applicant: | Gland Pharma Ltd |
Ingredient: | eribulin mesylate |
Patents: | 0 |
Pharmacology for NDA: 218047
Physiological Effect | Microtubule Inhibition |
Suppliers and Packaging for NDA: 218047
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218047 | ANDA | Apotex Corp. | 60505-6289 | 60505-6289-0 | 1 VIAL, SINGLE-DOSE in 1 CARTON (60505-6289-0) / 2 mL in 1 VIAL, SINGLE-DOSE |
ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218047 | ANDA | Gland Pharma Limited | 68083-592 | 68083-592-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68083-592-01) / 2 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1MG/2ML (0.5MG/ML) | ||||
Approval Date: | Apr 5, 2024 | TE: | AP | RLD: | No |
Complete Access Available with Subscription